Published papers
Academic conference presentation
    （Last updated : 2026-06-11 15:14:49）
  NAKAYAMA Takayuki
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine  Department of Urology
   Position   Assistant Professor
■ Published papers
1. Original article　 Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma. 2026/06/05
2. Original article　 Non-clear cell renal cell carcinoma has an immune-cold phenotype that affects response to immune checkpoint inhibitors. 2026/05/04
3. Original article　 Impact of first-line dual immuno-oncology combination therapy versus immuno-oncology plus tyrosine kinase inhibitor on outcomes of second-line VEGFR-TKI in advanced RCC: a real-world multi-institutional analysis. 2026/03
4. Original article　 Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma. 2026/01
5. Original article　 Comparison of real-world outcomes between nivolumab plus ipilimumab and lenvatinib plus pembrolizumab or nivolumab plus cabozantinib combination therapies for previously untreated advanced renal cell carcinoma. 2025/10
Display all(12)
■ Academic conference presentation
1. Experience of adjuvant pembrolizumab in patients with renal cell carcinoma: An initial report using short-term follow-up data. （Poster notice，General） 2026/04/23
2. Mid-term real-world outcome of combination therapy with immune checkpoint inhibitors and VEGFR-TKIs for renal cell carcinoma using minimum 3-year follow-up data. （Speech，General） 2026/04/23
3. Prognostic significance of B Cell and NK cell infiltration in the tumor immune microenvironment of renal cell carcinoma. （Poster notice，General） 2026/04/23
4. Immunotherapy outcomes and immune microenvironment profiles of patients with non-clear cell renal cell carcinoma. （Poster notice，General） 2025/09/26
5. Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma. （Poster notice，General） 2025/04/27
Display all(6)